Pemphigus vulgaris-associated Kaposi's sarcoma: response to paclitaxel and review of the literature
Systemic corticosteroids have long been the mainstay of treatment for pemphigus patients. However, the necessity of their high‐dose and long‐term administration has brought about a number of complications, sometimes causing significant morbidities. Maintaining a balance between therapeutic and undes...
Gespeichert in:
| Veröffentlicht in: | Journal of the European Academy of Dermatology and Venereology 2014-08, Vol.28 (8), p.987-994 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 994 |
|---|---|
| container_issue | 8 |
| container_start_page | 987 |
| container_title | Journal of the European Academy of Dermatology and Venereology |
| container_volume | 28 |
| creator | Balighi, K. Daneshpazhooh, M. Aghazadeh, N. Hejazi, P. Aryanian, Z. Azizpour, A. Rahbar, Z. Goodarzi, A. Chams-Davatchi, C. |
| description | Systemic corticosteroids have long been the mainstay of treatment for pemphigus patients. However, the necessity of their high‐dose and long‐term administration has brought about a number of complications, sometimes causing significant morbidities. Maintaining a balance between therapeutic and undesirable effects of medications is not always easily achievable. Therefore, additional treatment modalities are frequently needed to control side‐effects. Kaposi's sarcoma (KS) is a rare, potentially life‐threatening complication in this setting. Due to the rarity of data on pemphigus‐associated KS treatment, the best therapeutic approach is still undecided. Here, we report two cases of pemphigus patients who had developed extensive KS as a result of severe immunosuppressive therapy and were successfully treated with paclitaxel. In addition, we performed a review of literature to assess the results of the previously employed treatment modalities in this setting. |
| doi_str_mv | 10.1111/jdv.12348 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1566829258</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1566829258</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4668-bebe0220916b6e586ed97f200f44ba9e18b8289fdf1c18cf5e2e74b2fa2b99b03</originalsourceid><addsrcrecordid>eNqNkM9PFTEQxxujkSd48B8wvamHhf7cbb0ZVBBewBjUxEvTdmehuPu6trsP-O8tPuBmwlzmMJ_5zuSD0CtKdmmpvct2vUsZF-oJWlBRq4oTxZ-iBdGsrrSWegu9yPmSEEKpVM_RFhNcUCH5AvmvMIwX4XzOeD335zaFXNmcow92ghYf2zHm8CbjbJOPg32PE-QxrjLgKeLR-j5M9hp6bFdtGa0DXOHY4ekCcJlAstOcYAc962yf4eVd30bfP3862z-slqcHX_Y_LCsv6vK0AweEMaJp7WqQqoZWNx0jpBPCWQ1UOcWU7tqOeqp8J4FBIxzrLHNaO8K30dtN7pjinxnyZIaQPfS9XUGcs6GynGGaSfUIVDLeFEu36LsN6lPMOUFnxhQGm24MJeZWvyn6zT_9hX19Fzu7AdoH8t53AfY2wFXo4eb_Sebo44_7yGqzEfIE1w8bNv02dcMbaX6eHJjj5aH-dfTtzCz5X5GSnz8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552374348</pqid></control><display><type>article</type><title>Pemphigus vulgaris-associated Kaposi's sarcoma: response to paclitaxel and review of the literature</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Balighi, K. ; Daneshpazhooh, M. ; Aghazadeh, N. ; Hejazi, P. ; Aryanian, Z. ; Azizpour, A. ; Rahbar, Z. ; Goodarzi, A. ; Chams-Davatchi, C.</creator><creatorcontrib>Balighi, K. ; Daneshpazhooh, M. ; Aghazadeh, N. ; Hejazi, P. ; Aryanian, Z. ; Azizpour, A. ; Rahbar, Z. ; Goodarzi, A. ; Chams-Davatchi, C.</creatorcontrib><description>Systemic corticosteroids have long been the mainstay of treatment for pemphigus patients. However, the necessity of their high‐dose and long‐term administration has brought about a number of complications, sometimes causing significant morbidities. Maintaining a balance between therapeutic and undesirable effects of medications is not always easily achievable. Therefore, additional treatment modalities are frequently needed to control side‐effects. Kaposi's sarcoma (KS) is a rare, potentially life‐threatening complication in this setting. Due to the rarity of data on pemphigus‐associated KS treatment, the best therapeutic approach is still undecided. Here, we report two cases of pemphigus patients who had developed extensive KS as a result of severe immunosuppressive therapy and were successfully treated with paclitaxel. In addition, we performed a review of literature to assess the results of the previously employed treatment modalities in this setting.</description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.12348</identifier><identifier>PMID: 24341453</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Humans ; Immunosuppressive Agents - therapeutic use ; Male ; Middle Aged ; Paclitaxel - therapeutic use ; Pemphigus - complications ; Pemphigus - drug therapy ; Sarcoma, Kaposi - complications</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2014-08, Vol.28 (8), p.987-994</ispartof><rights>2013 European Academy of Dermatology and Venereology</rights><rights>2013 European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4668-bebe0220916b6e586ed97f200f44ba9e18b8289fdf1c18cf5e2e74b2fa2b99b03</citedby><cites>FETCH-LOGICAL-c4668-bebe0220916b6e586ed97f200f44ba9e18b8289fdf1c18cf5e2e74b2fa2b99b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjdv.12348$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjdv.12348$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24341453$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Balighi, K.</creatorcontrib><creatorcontrib>Daneshpazhooh, M.</creatorcontrib><creatorcontrib>Aghazadeh, N.</creatorcontrib><creatorcontrib>Hejazi, P.</creatorcontrib><creatorcontrib>Aryanian, Z.</creatorcontrib><creatorcontrib>Azizpour, A.</creatorcontrib><creatorcontrib>Rahbar, Z.</creatorcontrib><creatorcontrib>Goodarzi, A.</creatorcontrib><creatorcontrib>Chams-Davatchi, C.</creatorcontrib><title>Pemphigus vulgaris-associated Kaposi's sarcoma: response to paclitaxel and review of the literature</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Systemic corticosteroids have long been the mainstay of treatment for pemphigus patients. However, the necessity of their high‐dose and long‐term administration has brought about a number of complications, sometimes causing significant morbidities. Maintaining a balance between therapeutic and undesirable effects of medications is not always easily achievable. Therefore, additional treatment modalities are frequently needed to control side‐effects. Kaposi's sarcoma (KS) is a rare, potentially life‐threatening complication in this setting. Due to the rarity of data on pemphigus‐associated KS treatment, the best therapeutic approach is still undecided. Here, we report two cases of pemphigus patients who had developed extensive KS as a result of severe immunosuppressive therapy and were successfully treated with paclitaxel. In addition, we performed a review of literature to assess the results of the previously employed treatment modalities in this setting.</description><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Paclitaxel - therapeutic use</subject><subject>Pemphigus - complications</subject><subject>Pemphigus - drug therapy</subject><subject>Sarcoma, Kaposi - complications</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM9PFTEQxxujkSd48B8wvamHhf7cbb0ZVBBewBjUxEvTdmehuPu6trsP-O8tPuBmwlzmMJ_5zuSD0CtKdmmpvct2vUsZF-oJWlBRq4oTxZ-iBdGsrrSWegu9yPmSEEKpVM_RFhNcUCH5AvmvMIwX4XzOeD335zaFXNmcow92ghYf2zHm8CbjbJOPg32PE-QxrjLgKeLR-j5M9hp6bFdtGa0DXOHY4ekCcJlAstOcYAc962yf4eVd30bfP3862z-slqcHX_Y_LCsv6vK0AweEMaJp7WqQqoZWNx0jpBPCWQ1UOcWU7tqOeqp8J4FBIxzrLHNaO8K30dtN7pjinxnyZIaQPfS9XUGcs6GynGGaSfUIVDLeFEu36LsN6lPMOUFnxhQGm24MJeZWvyn6zT_9hX19Fzu7AdoH8t53AfY2wFXo4eb_Sebo44_7yGqzEfIE1w8bNv02dcMbaX6eHJjj5aH-dfTtzCz5X5GSnz8</recordid><startdate>201408</startdate><enddate>201408</enddate><creator>Balighi, K.</creator><creator>Daneshpazhooh, M.</creator><creator>Aghazadeh, N.</creator><creator>Hejazi, P.</creator><creator>Aryanian, Z.</creator><creator>Azizpour, A.</creator><creator>Rahbar, Z.</creator><creator>Goodarzi, A.</creator><creator>Chams-Davatchi, C.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201408</creationdate><title>Pemphigus vulgaris-associated Kaposi's sarcoma: response to paclitaxel and review of the literature</title><author>Balighi, K. ; Daneshpazhooh, M. ; Aghazadeh, N. ; Hejazi, P. ; Aryanian, Z. ; Azizpour, A. ; Rahbar, Z. ; Goodarzi, A. ; Chams-Davatchi, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4668-bebe0220916b6e586ed97f200f44ba9e18b8289fdf1c18cf5e2e74b2fa2b99b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Paclitaxel - therapeutic use</topic><topic>Pemphigus - complications</topic><topic>Pemphigus - drug therapy</topic><topic>Sarcoma, Kaposi - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Balighi, K.</creatorcontrib><creatorcontrib>Daneshpazhooh, M.</creatorcontrib><creatorcontrib>Aghazadeh, N.</creatorcontrib><creatorcontrib>Hejazi, P.</creatorcontrib><creatorcontrib>Aryanian, Z.</creatorcontrib><creatorcontrib>Azizpour, A.</creatorcontrib><creatorcontrib>Rahbar, Z.</creatorcontrib><creatorcontrib>Goodarzi, A.</creatorcontrib><creatorcontrib>Chams-Davatchi, C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Balighi, K.</au><au>Daneshpazhooh, M.</au><au>Aghazadeh, N.</au><au>Hejazi, P.</au><au>Aryanian, Z.</au><au>Azizpour, A.</au><au>Rahbar, Z.</au><au>Goodarzi, A.</au><au>Chams-Davatchi, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pemphigus vulgaris-associated Kaposi's sarcoma: response to paclitaxel and review of the literature</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2014-08</date><risdate>2014</risdate><volume>28</volume><issue>8</issue><spage>987</spage><epage>994</epage><pages>987-994</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><abstract>Systemic corticosteroids have long been the mainstay of treatment for pemphigus patients. However, the necessity of their high‐dose and long‐term administration has brought about a number of complications, sometimes causing significant morbidities. Maintaining a balance between therapeutic and undesirable effects of medications is not always easily achievable. Therefore, additional treatment modalities are frequently needed to control side‐effects. Kaposi's sarcoma (KS) is a rare, potentially life‐threatening complication in this setting. Due to the rarity of data on pemphigus‐associated KS treatment, the best therapeutic approach is still undecided. Here, we report two cases of pemphigus patients who had developed extensive KS as a result of severe immunosuppressive therapy and were successfully treated with paclitaxel. In addition, we performed a review of literature to assess the results of the previously employed treatment modalities in this setting.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>24341453</pmid><doi>10.1111/jdv.12348</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0926-9959 |
| ispartof | Journal of the European Academy of Dermatology and Venereology, 2014-08, Vol.28 (8), p.987-994 |
| issn | 0926-9959 1468-3083 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1566829258 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Humans Immunosuppressive Agents - therapeutic use Male Middle Aged Paclitaxel - therapeutic use Pemphigus - complications Pemphigus - drug therapy Sarcoma, Kaposi - complications |
| title | Pemphigus vulgaris-associated Kaposi's sarcoma: response to paclitaxel and review of the literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T12%3A57%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pemphigus%20vulgaris-associated%20Kaposi's%20sarcoma:%20response%20to%20paclitaxel%20and%20review%20of%20the%20literature&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Balighi,%20K.&rft.date=2014-08&rft.volume=28&rft.issue=8&rft.spage=987&rft.epage=994&rft.pages=987-994&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.12348&rft_dat=%3Cproquest_cross%3E1566829258%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552374348&rft_id=info:pmid/24341453&rfr_iscdi=true |